[Trazodone in the treatment of addiction]. 2011

Waldemar Kryszkowski, and Kinga Bobińska, and Monika Talarowska, and Agata Orzechowska, and Antoni Florkowski, and Piotr Gałecki
Klinika Psychiatrii Dorosłych, Uniwersytet Medyczny w Łodzi.

The problem of addiction to psychoactive substances (SPA) is an important aspect of modem psychiatric treatment. This is due to the increasing number of addicts, and reducing their increasing age. It is estimated that in the United States in 2006, people aged over 12 years of meeting criteria for dependence on SPA was 20-25 million. Other statistics report that in the same age group over the last year contact with these substances were 8-10 percent of the U.S. population. Therefore, it becomes an important issue the appropriate therapeutic treatment of addicts. The result of the search of drugs that help people to alcoholism treatment program, were studies involving trazodone. Counted among the SARI (serotonin reuptake inhibitor and antagonist), shows antagonism to serotonergic receptors (5-HT2 receptors), while an inhibitor of serotonin reuptake. Its performance was analyzed in individuals dependent on alcohol, benzodiazepines and opiates, as well as mixed addictions. Also raised the problem of influence of trazodone on the experience of pain, which maybe helpful in relieving withdrawal symptoms. The data show a positive effect of trazodone in individuals addicted to the SPA, although the mechanism by which trazodone works in the body is very complex and not yet fully understood. Its advantage is the relatively small panel of side effects. Although many of the analyzed studies were not placebo-controlled, the results are so promising that you can recommend on the basis of trazodone therapy in individuals addicted to the SPA.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000437 Alcoholism A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4) Alcohol Abuse,Alcoholic Intoxication, Chronic,Ethanol Abuse,Alcohol Addiction,Alcohol Dependence,Alcohol Use Disorder,Abuse, Alcohol,Abuse, Ethanol,Addiction, Alcohol,Alcohol Use Disorders,Chronic Alcoholic Intoxication,Dependence, Alcohol,Intoxication, Chronic Alcoholic,Use Disorders, Alcohol
D014196 Trazodone A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309) AF-1161,Apo-Trazodone,Deprax,Desyrel,Gen-Trazodone,Molipaxin,Novo-Trazodone,Nu-Trazodone,PMS-Trazodone,Ratio-Trazodone,Thombran,Tradozone,Trazodon Hexal,Trazodon-Neuraxpharm,Trazodone Hydrochloride,Trazon,Trittico,AF 1161,AF1161,Apo Trazodone,Gen Trazodone,Novo Trazodone,Nu Trazodone,PMS Trazodone,Ratio Trazodone,RatioTrazodone,Trazodon Neuraxpharm,TrazodonNeuraxpharm
D016739 Behavior, Addictive The observable, measurable, and often pathological activity of an organism that portrays its inability to overcome a habit resulting in an insatiable craving for a substance or for performing certain acts. The addictive behavior includes the emotional and physical overdependence on the object of habit in increasing amount or frequency. Addictive Behavior,Addictive Behaviors,Behaviors, Addictive
D017367 Selective Serotonin Reuptake Inhibitors Compounds that specifically inhibit the reuptake of serotonin in the brain. 5-HT Uptake Inhibitor,5-HT Uptake Inhibitors,5-Hydroxytryptamine Uptake Inhibitor,5-Hydroxytryptamine Uptake Inhibitors,SSRIs,Selective Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitors,Serotonin Uptake Inhibitor,Serotonin Uptake Inhibitors,Inhibitors, 5-HT Uptake,Inhibitors, 5-Hydroxytryptamine Uptake,Inhibitors, Serotonin Reuptake,Inhibitors, Serotonin Uptake,Reuptake Inhibitors, Serotonin,Uptake Inhibitors, 5-HT,Uptake Inhibitors, 5-Hydroxytryptamine,Uptake Inhibitors, Serotonin,Inhibitor, 5-HT Uptake,Inhibitor, 5-Hydroxytryptamine Uptake,Inhibitor, Serotonin Reuptake,Inhibitor, Serotonin Uptake,Reuptake Inhibitor, Serotonin,Uptake Inhibitor, 5-HT,Uptake Inhibitor, 5-Hydroxytryptamine,Uptake Inhibitor, Serotonin
D019966 Substance-Related Disorders Disorders related to substance use or abuse. Chemical Dependence,Drug Abuse,Drug Addiction,Drug Dependence,Drug Habituation,Drug Use Disorder,Drug Use Disorders,Organic Mental Disorders, Substance-Induced,Substance Abuse,Substance Dependence,Substance Related Disorder,Substance Use,Substance Use Disorder,Substance Use Disorders,Prescription Drug Abuse,Substance Addiction,Abuse, Drug,Abuse, Prescription Drug,Abuse, Substance,Addiction, Drug,Addiction, Substance,Chemical Dependences,Dependence, Chemical,Dependence, Drug,Dependence, Substance,Dependences, Chemical,Disorder, Drug Use,Disorder, Substance Related,Disorder, Substance Use,Disorders, Substance Related,Drug Abuse, Prescription,Habituation, Drug,Organic Mental Disorders, Substance Induced,Related Disorder, Substance,Related Disorders, Substance,Substance Abuses,Substance Uses,Use, Substance

Related Publications

Waldemar Kryszkowski, and Kinga Bobińska, and Monika Talarowska, and Agata Orzechowska, and Antoni Florkowski, and Piotr Gałecki
June 1999, Journal of clinical psychopharmacology,
Waldemar Kryszkowski, and Kinga Bobińska, and Monika Talarowska, and Agata Orzechowska, and Antoni Florkowski, and Piotr Gałecki
January 1977, Psychiatria polska,
Waldemar Kryszkowski, and Kinga Bobińska, and Monika Talarowska, and Agata Orzechowska, and Antoni Florkowski, and Piotr Gałecki
August 1986, Journal of clinical psychopharmacology,
Waldemar Kryszkowski, and Kinga Bobińska, and Monika Talarowska, and Agata Orzechowska, and Antoni Florkowski, and Piotr Gałecki
July 1983, The Journal of clinical psychiatry,
Waldemar Kryszkowski, and Kinga Bobińska, and Monika Talarowska, and Agata Orzechowska, and Antoni Florkowski, and Piotr Gałecki
October 1973, Current therapeutic research, clinical and experimental,
Waldemar Kryszkowski, and Kinga Bobińska, and Monika Talarowska, and Agata Orzechowska, and Antoni Florkowski, and Piotr Gałecki
December 1980, The Journal of clinical psychiatry,
Waldemar Kryszkowski, and Kinga Bobińska, and Monika Talarowska, and Agata Orzechowska, and Antoni Florkowski, and Piotr Gałecki
October 1973, Current therapeutic research, clinical and experimental,
Waldemar Kryszkowski, and Kinga Bobińska, and Monika Talarowska, and Agata Orzechowska, and Antoni Florkowski, and Piotr Gałecki
July 1979, Psychopharmacology bulletin,
Waldemar Kryszkowski, and Kinga Bobińska, and Monika Talarowska, and Agata Orzechowska, and Antoni Florkowski, and Piotr Gałecki
June 2010, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
Waldemar Kryszkowski, and Kinga Bobińska, and Monika Talarowska, and Agata Orzechowska, and Antoni Florkowski, and Piotr Gałecki
July 1976, Current therapeutic research, clinical and experimental,
Copied contents to your clipboard!